Communiqués Indivior Pharmaceuticals, Inc.

Actions

INDV

US45579U1097

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 09/07/2026			Varia. 5j.	Varia. 1 janv.
41,30 ^USD	+1,00%		+2,61%	+15,11%

18/06	INDIVIOR PHARMACEUTICALS, INC. : Barclays persiste à l'achat	ZM
10/06	Indivior Pharmaceuticals : cession de titres par un dirigeant pour 1'357'200 dollars, selon un document de la SEC	MT

Communiqués

21/05	Indivior Pharmaceuticals - New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization	AQ
30/04	Indivior Pharmaceuticals : FINAL Indivior Q1 2026 Press Release 2026.04.30	PU
30/04	Indivior Pharmaceuticals : FINAL Indivior 1Q26 Financial Results Deck Site Version	PU
30/04	Indivior Pharmaceuticals : FINAL Indivior Corporate Investor Deck April 27	PU
27/04	Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder	AQ
01/04	Indivior Pharmaceuticals - New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities	AQ
12/03	Indivior Pharmaceuticals - New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder	AQ
26/02	Indivior Pharmaceuticals : FINAL Indivior Corporate Investor Deck	PU
26/02	Indivior Pharmaceuticals : FINAL Press Release	PU
26/02	Indivior Pharmaceuticals : FINAL Indivior Q4 Financial Results Deck	PU
29/01	Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26??	AQ
26/01	Indivior Announces Completion of Redomiciliation to the United States	GL
08/01	Indivior : Financial Document	PU
08/01	Indivior Provides Full-Year 2026 Financial Guidance and Business Update	GL
22/12	Indivior Announces Inclusion in the S&P SmallCap 600® Index	PR
17/12	New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations	PR
20/11	Indivior Concludes Legacy U.S. Department of Justice Matter	PR
19/11	Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference	PR
18/11	Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine	AQ
03/11	Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine	PR
30/10/25	Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance	PR
28/10/25	Indivior to Participate in the Stifel 2025 Healthcare Conference	PR
16/10/25	Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th	PR
15/10/25	Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment	PR
01/10/25	Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation	PR